Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Entrectinib + PAC-1|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Entrectinib||Rozlytrek||RXDX-101||ALK Inhibitor 23 ROS1 Inhibitor 14 Trk Receptor Inhibitor (Pan) 24||Rozlytrek (entrectinib) inhibits the activity of TrkA/B/C, Ros1 fusion proteins, and Alk, which leads to induction of apoptosis and inhibition of proliferation in cells expressing these kinases (PMID: 27003761). Rozlytrek (entrectinib) is FDA approved for use in patients with ROS1 positive non-small cell lung cancer and in adult and pediatric (12 years and older) patients with solid tumors harboring NRTRK fusions without known acquired resistance mutations (FDA.gov).|
|PAC-1||VO-100||PAC-1 is a small molecule activator of procaspase 3, which occurs via inhibition of zinc ions, resulting in autoactivation and thus, may lead to apoptotis and anti-tumor activity (PMID: 19281821, PMID: 27297867).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04589832||Phase Ib/II||Entrectinib + PAC-1||Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma||Recruiting||USA||0|